Lung Adenocarcinoma That Transformed to Small Cell Cancer After Recurrence

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 1%-24%; no druggable driver alteration identified

Metastatic Site: brain, liver

After treatment for the small-cell-transformed recurrence, the liver metastases showed sustained regression and progression-free survival had reached 13 months by September 2024.

PubMed CentralRead more →

MET Y1003N-Mutant Lung Adenocarcinoma Responding to Tepotinib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: MET mutation

Metastatic Site: bone

Tepotinib produced an 8-month response after many earlier treatments, but the cancer later recurred and she died about 3 years after treatment began.

PubMed CentralRead more →

Long-Lasting Pembrolizumab Response in Stage III Lung Adenocarcinoma With STK11, TP53 and RB1 Mutations

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: TP53 and RB1 mutations; high tumor mutational burden; PD-L1 70%

Pembrolizumab produced a partial response within 3 months, improved his breathing and fatigue, and was continued for more than 2 years without significant immune-related toxicity.

PubMed CentralRead more →

Stage IIIA squamous lung cancer: surgery after nivolumab-related complications

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: PD-L1 TPS 99% before treatment; PD-L1 TPS 70% in postoperative hilar lymph node; TPOAb and TgAb normal during thyroiditis workup

As of January 2025, the patient had no recurrence 7 months after neoadjuvant nivolumab/carboplatin/paclitaxel and 5 months after thoracoscopic right upper lobectomy with lymph node dissection.

PubMed CentralRead more →

Therapy-related acute promyelocytic leukemia during lung cancer treatment

Patient Info: Anonymized, Male, 70+

Biomarkers: Therapy-related APL with t and PML/RARA fusion; CD33 positive

The patient died 6 hours after symptom onset on day 6 of induction therapy for therapy-related acute promyelocytic leukemia.

PubMed CentralRead more →

Lung Adenosquamous Carcinoma Arising From a Long-Standing Bronchogenic Cyst

Patient Info: Anonymized, female, 70+

Biomarkers: KRAS G12D mutation; PD-L1 TPS 60%; EGFR/BRAF/ROS1/ALK negative

She remained in remission 2.4 years after surgery despite stopping atezolizumab early because of immune-mediated colitis.

PubMed CentralRead more →

Stage IIB squamous cell lung cancer: pathological complete response after chemo-immunotherapy and surgery

Patient Info: Anonymized, Male, 60s | Stage II

Biomarkers: PD-L1 >85%; P40-positive; TTF-1-negative; CEA 1.2 ng/mL; cytokeratin 19 fragments 1.7 ng/mL; pro-gastrin-releasing peptide 54 pg/mL

No recurrence for 1 year and 7 months without further treatment after transbronchoscopic resection, pembrolizumab-based chemoimmunotherapy, pneumonitis management, and sleeve resection showing pathological complete response.

PubMed CentralRead more →

Stage 3 squamous cell lung cancer: major response to chemo-immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: PD-L1 30-40%

After neoadjuvant chemoimmunotherapy and sleeve right lower lobectomy, pathology showed major pathological response with negative margins, and no metastasis or recurrence was observed 6 months after surgery.

PubMed CentralRead more →

Stage IVA pulmonary squamous cell carcinoma with nasal and bone metastases: response after paclitaxel, carboplatin, and tislelizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: PD-L1 15%

Metastatic Site: nasal region/skin; bone (left acromion)

The lung tumor and nasal metastasis regressed after paclitaxel/carboplatin plus tislelizumab, symptoms improved, no immune-related pneumonitis/colitis/hepatitis occurred, and progression-free survival exceeded 12 months.

PubMed CentralRead more →

Stage 4 lung cancer: complete response to chemoimmunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 20 duplication with PD-L1 TPS 70%; P40/CK5/6 positive squamous markers; Ki-67 60%.

Metastatic Site: right adrenal gland; possible adjacent…

As of May 7, 2024, CT follow-up showed no evidence of disease after chemoimmunotherapy, conversion surgery with pathologic complete response, and pembrolizumab maintenance.

PubMed CentralRead more →

Stage IV lung cancer: brain metastasis complete response after chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS-mutated; BRG-1 partial loss; PD-L1 TPS 5%; CPS 20

Metastatic Site: brain (right cerebellar hemisphere)

The right cerebellar brain metastasis completely resolved and chest CT showed only postsurgical changes after carrelizumab plus paclitaxel/carboplatin; immune-mediated adrenal insufficiency improved with systemic glucocorticoids.

PubMed CentralRead more →

Stage III Large Cell Lung Cancer With Complete Response to Pembrolizumab-Based Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PD-L1 TPS >60%; no actionable gene mutations identified

Imaging showed complete response of the recurrent hilar and mediastinal lymph nodes, and he remained progression-free through 24 cycles of treatment.

PubMed CentralRead more →

Small Cell Lung Cancer With Paraneoplastic Cushing Syndrome Treated With Immunochemotherapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 negative; low tumor mutation burden; microsatellite stable

Metastatic Site: liver, abdominal wall, left ilium

He lived 20 months after diagnosis. After repeated treatment responses and later progression, he died in September 2023 from respiratory and cardiac failure during a severe infection following treatment-related myelosuppression.

PubMed CentralRead more →

Stage 3 squamous lung cancer: pathological complete response after immunotherapy and surgery

Patient Info: Anonymized, Male, 50s | Stage III

Pathologic complete response after DEB-BACE plus tislelizumab followed by thoracoscopic right middle/lower lobectomy and lymph-node dissection; postoperative chemo-immunotherapy continued and reexaminations were stable.

PubMed CentralRead more →

Stage IV lung adenocarcinoma: ROS1 fusion detected after immunotherapy resistance and partial response to entrectinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial lung adenocarcinoma markers supported lung origin; PD-L1 <1%, no target found at first. Later testing found CD74-ROS1 fusion.

Metastatic Site: brain, bilateral lung lesions

As of December 2024, repeat imaging after entrectinib showed partial response in lung disease and regression of brain metastases, with the patient stable and willing to continue treatment.

PubMed CentralRead more →

Stage IV lung adenocarcinoma: clinical complete remission with pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No EGFR/ALK/BRAF driver alteration; PD-L1 <1%; high TMB in tissue and blood; immune-cell markers reported.

Metastatic Site: bilateral lungs, mediastinal lymph nodes, right hilar…

Clinical complete remission by RECIST while receiving pembrolizumab monotherapy for driver-negative, PD-L1-negative, high-TMB Stage IV lung adenocarcinoma.

PubMed CentralRead more →

Stage IV Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female | Stage IV

Metastatic Site: lungs, lymph nodes

As of December 2024, Natalie had restarted chemotherapy after progression, and the current chemotherapy had stopped growth for the moment while she continued transplant evaluation.

The Patient StoryRead more →

Stage IV Lung Adenocarcinoma With Delayed Pembrolizumab-Related Pneumonitis

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: contralateral lung

After brachytherapy and continued pembrolizumab, imaging 1 year later showed a smaller right hilar lesion with otherwise stable disease. She later recovered from delayed pembrolizumab-related pneumonitis after immunotherapy had been stopped.

PubMed CentralRead more →

ROS1-Positive Stage III Pulmonary Sarcomatoid Carcinoma With Complete Pathologic Response

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: ROS1 rearrangement; TP53 mutation; PD-L1 TPS 0%

No recurrence was seen for more than 30 months after surgery following a complete pathologic response.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response to Neoadjuvant Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PIK3CA mutation; TP53 mutation; PD-L1 TPS 5%

No recurrence was detected for more than 29 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response and No Recurrence

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: NRAS mutation; TP53 mutation; PD-L1 TPS 60%

No recurrence was detected for more than 27 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma Treated With Neoadjuvant Immunochemotherapy and Surgery

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: TP53 mutation; PD-L1 TPS 40%

No recurrence was detected for more than 30 months after surgery.

PubMed CentralRead more →

Lung Adenocarcinoma With Immune-Related Abdominal Inflammation and Later Bone Progression

Patient Info: Anonymized, male | Stage IV

Biomarkers: PD-L1 30%; KRAS G13X mutation; EGFR/ALK/ROS1 negative

Metastatic Site: bone

After several periods of response or stability, lymph-node progression recurred and bone progression was documented in July 2024. Another treatment line was being planned.

PubMed CentralRead more →

Stage IV HER2-Positive Non-Small Cell Lung Cancer: Samantha's Patient Story

Patient Info: Samantha, Female | Stage IV

Biomarkers: HER2 mutation

Metastatic Site: Lungs/pleural fluid; liver

As of November 2024, Samantha reported a 55% reduction across the board on chemotherapy plus immunotherapy, few side effects, improved energy, and enough function to hike, work, and feel more like herself.

The Patient StoryRead more →